RxDoctor Payments Data

Josephine Sims

Family · Covington, LANPI 1023430725

Payments from drug & device makers

$11,057in general payments, 2019–2025

Across 635 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • GSK$1K
  • Lilly USA, LLC$968
  • Bayer$850
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$11,057100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,057 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$10,598
Medicare patients
67
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$45,995
MounjaroTirzepatide34$45,730
KerendiaFinerenone19$15,026
JardianceEmpagliflozin17$14,520
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$2,153
Tresiba Flextouch U-100Insulin Degludec11$2,123
SynthroidLevothyroxine Sodium26$1,952
Levothyroxine Sodium93$903
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$869
Atorvastatin Calcium86$811
Testosterone Cypionate11$753
Losartan Potassium43$735
Metoprolol Succinate17$677
Pantoprazole Sodium48$670
Bupropion XlBupropion Hcl21$619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,162$45,99542 claims
Lilly USA, LLCMounjaro$968$45,73034 claims
BayerKerendia$850$15,02619 claims
Boehringer IngelheimJardiance$445$14,52017 claims
AbbVieSynthroid$1,340$1,95226 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$90393 claims
Almatica Pharma LLCSertraline Hcl$58$17337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →